Skip to main content

Table 1 Characteristics of studies included in the systematic review

From: The effect of hyoscine n- butylbromide on labor progress: A systematic review

STUDY

Location

Study type

Age (y) Mean ± SD

No. of participants

Gravidity of participants

Treatment onset

Intervention with dosage

Control with dosage

Duration of first stage of labour Mean ± SD

HBB

Placebo

HBB

Placebo

HBB

Placebo

Iravani 2006 [21]

Iran

RCT

NA

NA

50

50

Primigravidas

4 cm dilatation and 50% cervical effacement

HBB 20 mg (1 ml) intravenously

Normal saline 1 ml intravenously

166.56 ± 12.85

255.98 ± 25.21

Samuels 2007 [14]

West Indies, Jamaica

RCT

25.0 ± 6.0

26.9 ± 6.2

60

69

Primi- and multigravida

4–5 cm dilatation

HBB 20 mg (1 ml) intravenously

Normal saline 1 ml intravenously

156 ± 121.08

228 ± 121.08

Makvand 2010

Iran

RCT

NA

NA

65

65

Primigravidas

Established labour,3–4 cm dilatation

20 mg Rectal Suppository HBB

1 Rectal Suppository placebo

141.02 ± 81.86

230.09 ± 169.58

Al Qahtan 2011 [34]

Saudi Arabia

RCT

23.9 ± 4.04

24.4 ± 5.36

52

45

Primigravidas

Established labour,3–4 cm dilatation

2 mL HBB (40 mg) intramuscularly

2 mL normal saline intramuscularly

165 ± 67

214 ± 79

Sekhavat 2012 [20]

Iran

RCT

26.1 ± 5.4

26.9 ± 4.8

94

94

Multigravidas

3–4 cm dilatation

HBB 20 mg (1 ml) intravenously

Normal saline 1 ml intravenously

186.8 ± 125.6

260.4 ± 120.9

Al-Khishali 2012 [31]

Iraq

RCT

25.9 ± 5.2

25.7 ± 5.5

100

100

Primi- and multigravida

3–4 cm dilatation

HBB 20 mg (1 ml) intravenously

Normal saline 1 ml intravenously

167.7 ± 76.2

193.8 ± 58.0

Alani 2012 [30]

Iraq

RCT

27.62 ± 4.179

27.62 ± 3.771

130

130

Multigravidas

4 cm dilatation

HBB 40 mg (2 ml) intravenously

Normal saline2 ml intravenously

142.69 ± 44.30

258.00 ± 23.223

Treviño-Salinas 2015 [25]

Mexico

RCT

25.65 ± 6.555

25.37 ± 6.98

43

43

Primi- and multigravida

4 cm dilatation Or more

20 mg of BBH (diluted in 9 ml of saline soalution) intravenously on two occasions with an interval of 1 h

10 ml of saline solution intravenously on two occasions with an interval of 1 h

151.186 ± 84.657

139.93 ± 92.484

Kirim 2015 [10]

Turkey

RCT

25.90 ± 6.11

26.18 ± 5.31

197

185

Primi- and multigravida

dilatation of 4 cm and 50% cervical effacement

HBB 20 mg (1 ml) intravenously

Normal saline 1 ml intravenously

191.13 ± 43.06

248.21 ± 66.16

Edessy 2015 [16]

Egypt

RCT

22.5 ± 1.91

22.3 ± 1.49

44

42

Primigravidas

4–5 cm dilatation

HBB 20 mg (1 ml) intravenously

Normal saline 1 ml intravenously

138 ± 37.2

186 ± 46.8

Bashir 2016 [15]

Pakistan

RCT

NA

NA

54

54

Primi- and multigravida

4 cm or more cervical dilation

HBB 20 mg (1 ml) intravenously

Normal saline 1 ml intravenously

178.98 ± 92.44

214.74 ± 147.44

Shirazi 2016 [19]

Iran

RCT

27(4.56)

27.4(3.94)

30

30

Primi- and multigravida (until G4)

The active phase of labor

HBB 40 mg (2 ml) intravenously

Normal saline 2 ml intravenously

426 ± 279

639 ± 237.6

Narappagari 2016 [33]

Puducherry

RCT

24.62 ± 3.53

24.67 ± 3.91

100

100

Primi- and multigravida

Cervical dilatation of 3–4 cm

HBB 20 mg (1 ml) intravenously

Normal saline 1 ml intravenously

114 ± 75

182 ± 88

Imaralu 2017 [17]

Nigeria

RCT

28.03 ± 4.79

28.33 ± 5.34

80

80

Primi- and multigravida (until G4)

Cervical dilatation of 4 cm

HBB 20 mg (1 ml) intravenously

Normal saline 1 ml intravenously

365.11 ± 37.32

388.46 ± 51.65

Kandil 2017 [18]

Egypt

RCT

23.78 ± 2.65

23.21 ± 2.80

55

55

Primigravidas

The active phase of labor

HBB 40 mg (2 ml) intramuscularly

Normal saline 2 ml intramuscularly

208.16 ± 17.24

258.16 ± 15.27

Namaziyan 2017 [35]

Iran

RCT

NA

NA

150

150

Primigravidas

Dilatation of 4 cm and 30–40% cervical effacement

20 mg HBB (1 ml) and 2 cc distilled water intravenously

3 cc water distilled intravenously

405.36 ± 108

350.87 ± 210

Phahlavani-Sheikhi 2017 [22]

Iran

RCT

NA

NA

55

50

Primigravidas

Dilatation of 4 cm

HBB 40 mg (2 ml) intravenously

Normal saline 2 ml intravenously

181 ± 59.1

208.2 ± 48.5

Barau 2018 [24]

Nigeria

RCT

29.9 ± 4.9

30.2 ± 4.8

59

64

Primi- and multigravida

Dilatation of 4–5 cm

HBB 20 mg (1 ml) intravenously

Normal saline 1 ml intravenously

279.1 ± 134.0

269.3 ± 135.9

Maged 2018 [36]

Egypt

RCT

24.15 ± 3.82

24.43 ± 3.73

40

40

Primigravidas

Dilatation of 3–4 cm and 50% cervical effacement

HBB 20 mg (1 ml) + 1 ml saline intravenously

Normal saline 2 ml intravenously

187.73 ± 20.92

231.39 ± 33.14

Ibrahim 2019 [32]

Nigeria

RCT

27 ± 5

25 ± 3

102

102

Primi- and multigravida

Dilatation of 4 cm

HBB 40 mg (2 ml) intravenously

Normal saline 2 ml intravenously

344 ± 131

412 ± 175